Advances in ultra-high field MRI for the clinical management of patients with brain tumors

Current Opinion in Neurology

Volumn 24, Issue 6, 2011, Pages 605-615

  Lupo, Janine M ^a   Li, Yan ^a   Hess, Christopher P ^a   Nelson, Sarah J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

7 T; brain tumors; treatment effects; ultra high field MRI

Indexed keywords

ANGIOGENESIS INHIBITOR; DEOXYHEMOGLOBIN; FERUMOXYTOL; GADOLINIUM; ISOCITRATE DEHYDROGENASE; N ACETYLASPARTIC ACID; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ASTROCYTOSIS; BRAIN METASTASIS; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAVERNOUS HEMANGIOMA; CHEMORADIOTHERAPY; CYTOREDUCTIVE SURGERY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; GLIOMA; HUMAN; LHERMITTE DUCLOS DISEASE; LUNG CARCINOMA; MICROVASCULATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PILOCYTIC ASTROCYTOMA; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION NECROSIS; REVIEW; SINGLE DRUG DOSE; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR GROWTH; ULTRAHIGH FIELD MAGNETIC RESONANCE IMAGING;

BIOLOGICAL MARKERS; BRAIN; BRAIN NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NERVE FIBERS, MYELINATED; SENSITIVITY AND SPECIFICITY;

EID: 81855165013     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834cd495     Document Type: Review

References (81)

1. Pirzkall A, McGue C, Saraswathy S, et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2009; 11:842-852.
2. Park I, Tamai G, Lee MC, et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to preradiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 2007; 69:381-389. (Pubitemid 47380095)
3. Saraswathy S, Crawford FW, Lamborn KR, et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009; 91:69-81.
4. Crawford FW, Khayal IS, McGue C, et al. Relationship of presurgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol 2009; 91:337-351.
5. Chang SM, Nelson S, Vandenberg S, et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol 2009; 92:401-415.
6. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171:1479-1486. (Pubitemid 28531609)
7. Castillo M, Smith JK, Kwock L, et al. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001; 22:60-64. (Pubitemid 32105356)
8. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005; 102:5524-5529. (Pubitemid 40530291)
9. Gupta RK, Cloughesy TF, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000; 50:215-226. (Pubitemid 32192873)
10. Lupo JM, Cha S, Chang SM, Nelson SJ. Analysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma. AJNR Am J Neuroradiol 2007; 28:1455-1461. (Pubitemid 47462926)
11. Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am 2009; 19:527-557.
12. Li Y, Lupo JM, Polley MY, et al. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro Oncol 2011; 13:546-557.
13. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963-1972.
14. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009; 22:633-638.
15. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9:453-461. (Pubitemid 351597795)
16. Rooney WD, Johnson G, Li X, et al. Magnetic field and tissue dependencies of human brain longitudinal 1H2O relaxation in vivo. Magn Reson Med 2007; 57:308-318. (Pubitemid 46214534)
17. Ladd ME. High-field-strength magnetic resonance: potential and limits [review]. Top Magn Reson Imaging 2007; 18:139-152. (Pubitemid 47051884)
18. Duyn JH, van Gelderen P, Li TQ, et al. High-field MRI of brain cortical substructure based on signal phase. Proc Natl Acad Sci USA 2007; 104:11796-11801. (Pubitemid 47175092)
19. Hammond KE, Lupo JM, Xu D, et al. Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases. Neuroimage 2008; 39:1682-1692.
20. Zhong K, Leupold J, von Elverfeldt D, Speck O. The molecular basis for gray and white matter contrast in phase imaging. Neuroimage 2008; 40:1561-1566.
21. Chen Z, Johnston LA, Kwon DH, et al. An optimised framework for reconstructing and processing MR phase images. Neuroimage 2010; 49:1289-1300.
22. Rauscher A, Sedlacik J, Barth M, et al. Magnetic susceptibility-weighted MR phase imaging of the human brain. AJNRAmJ Neuroradiol 2005; 26:736-742. (Pubitemid 43079761)
23. Abduljalil AM, Schmalbrock P, Novak V, Chakeres DW. Enhanced gray and white matter contrast of phase susceptibility-weighted images in ultra-highfield magnetic resonance imaging. J Magn Reson Imaging 2003; 18:284-290. (Pubitemid 37046508)
24. Koopmans PJ, Manniesing R, Niessen WJ, et al. MR venography of the human brain using susceptibility weighted imaging at very high field strength. MAGMA 2008; 21:149-158.
25. Christoforidis GA, Grecula JC, Newton HB, et al. Visualization of microvascularity in glioblastoma multiforme with 8-T high-spatial-resolution MR imaging. AJNR Am J Neuroradiol 2002; 23:1553-1556. (Pubitemid 35154997)
26. Christoforidis GA, Kangarlu A, Abduljalil AM, et al. Susceptibility-based imaging of glioblastoma microvascularity at 8 T: correlation of MR imaging and postmortem pathology. AJNR Am J Neuroradiol 2004; 25:756-760. (Pubitemid 38657656)
27. Lupo JM, Chang SM, Nelson SJ. Using 7T susceptibility-weighted imaging to aid in the characterization of high-grade gliomas. In: Proceedings of the 16th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 3-9 May 2008; Toronto, Ontario. p. 2821.
28. Lupo JM, Hammond KE, Chang SM, Nelson SJ. Imaging treatment effects in brain tumors using SWI. In: Proceedings of the Society for Neuro-Oncology 12th Annual Scientific Meeting; 15-18 November 2007; Dallas, Texas, USA.
29. Lupo JM, Banerjee S, Hammond KE, et al. GRAPPA-based susceptibilityweighted imaging of normal volunteers and patients with brain tumor at 7 T. Magn Reson Imaging 2009; 27:480-488.
30. Peters AM, Brookes MJ, Hoogenraad FG, et al. T2 measurements in human brain at 1.5, 3 and 7 T. Magn Reson Imaging 2007; 25:748-753.
31. Wright PJ, Mougin OE, Totman JJ, et al. Water proton T1 measurements in brain tissue at 7, 3, and 1.5 T using IR-EPI, IR-TSE, and MPRAGE: results and optimization. MAGMA 2008; 21:121-130.
32. Zwanenburg JJ, Hendrikse J, Visser F, et al. Fluid attenuated inversion recovery (FLAIR) MRI at 7.0 Tesla: comparison with 1.5 and 3.0 Tesla. Eur Radiol 2010; 20:915-922.
33. Visser F, Zwanenburg JJ, Hoogduin JM, Luijten PR. High-resolution magnetization-prepared 3D-FLAIR imaging at 7.0 Tesla. Magn Reson Med 2010; 64:194-202.
34. Madelin G, Oesingmann N, Inglese M. Double Inversion RecoveryMRI with fat suppression at 7 tesla: initial experience. J Neuroimaging 2010; 20:87-92.
35. Van de Moortele PF, Auerbach EJ, Olman C, et al. T1 weighted brain images at 7 Tesla unbiased for Proton Density, T2 contrast and RF coil receive B1 sensitivity with simultaneous vessel visualization. Neuroimage 2009; 46:432-446.
36. Mö nninghoff C, Maderwald S, Theysohn JM, et al, Imaging of brain metastases of bronchial carcinomas with 7 T MRI: initial results. Rofo, 2010, 182, 764-772.
37. Schlamann M, Maderwald S, Becker W, et al. Cerebral cavernous hemangiomas at 7 Tesla: initial experience. Acad Radiol 2010; 17:3-6.
38. Moenninghoff C, Kraff O, Schlamann M, et al. Assessing a dysplastic cerebellar gangliocytoma (L'hermitte-Duclos disease) with 7T MR imaging. Korean J Radiol 2010; 11:244-248.
39. Moenninghoff C, Maderwald S, Theysohn JM, et al. Imaging of adult astrocytic brain tumours with 7 T MRI: preliminary results. Eur Radiol 2010; 20:704-713.
40. Noebauer-Huhmann IM, Szomolanyi P, Juras V, et al. Gadolinium-based magnetic resonance contrast agents at 7 Tesla: in vitro T1 relaxivities in human blood plasma. Invest Radiol 2010; 45:554-558.
41. Njus JM, Dosa E, Gahramanov S, et al. Initial experience with ferumoxytol dynamic susceptibility MRI in human brain at 3T and 7T. In: Proceedings from the 18th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 1-7 May 2010; Stockholm, Sweden. p. 2216.
42. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies [a review]. J Cereb Blood Flow Metab 2010; 30:15-35.
43. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibilityweighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011; 79:514-523.
44. Akter M, Hirai T, Hiai Y, et al. Detection of hemorrhagic hypointense foci in the brain on susceptibility-weighted imaging clinical and phantom studies. Acad Radiol 2007; 14:1011-1019. (Pubitemid 47248335)
45. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging [review]. J Magn Reson Imaging 2005; 23:1-25. (Pubitemid 40269946)
46. Haacke EM, DelProposto ZS, Chaturvedi S, et al. Imaging cerebral amyloid angiopathy with susceptibility-weighted imaging. AJNR Am J Neuroradiol 2007; 28:316-317. (Pubitemid 46281054)
47. Lupo JM, Chuang CF, Chang SM, et al. Tesla susceptibility-weighted imaging to assess the effects of radiation therapy on normal appearing brain in patients with glioma. Int J Radiat Oncol Biol Phys (in press).
48. Conijn MM, Geerlings MI, Luijten PR, et al. Visualization of cerebral microbleeds with dual-echo T2-weighted magnetic resonance imaging at 7.0 T. J Magn Reson Imaging 2010; 32:52-59.
49. Holdsworth SJ, Skare S, Rexford DN, et al. Robust GRAPPA-accelerated diffusion-weighted readout-segmented (RS)-EPI. Magn Reson Med 2009; 62:1629-1640.
50. Heidemann RM, Porter DA, Anwander A, et al. Diffusion imaging in humans at 7T using readout-segmented EPI and GRAPPA. Magn Reson Med 2010; 64:9-14.
51. Von Morze C, Kelley DA, Shepherd TM, et al. Reduced field-of-view diffusionweighted imaging of the brain at 7T. Magn Reson Imag 2010; 28:1541-1545.
52. Heidemann RM, Anwander A, Knoesche T, et al. Isotropic high resolution diffusion-tensor imaging in humans at 7 T. In: Proceedings of the 18th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 2010; Stockholm, Sweden. p. 1610.
53. McKnight TR, Noworolski SM, Vigneron DB, et al. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J Magn Reson Imaging 2001; 13:167-177. (Pubitemid 32066652)
54. Otazo R, Mueller B, Ugurbil K, et al. Signal-to-noise ratio and spectral linewidth improvements between 1.5 and 7 Tesla in proton echo-planar spectroscopic imaging. Magn Reson Med 2006; 56:1200-1210. (Pubitemid 44865301)
55. Tkac I, Oz G, Adriany G, et al. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 2009; 62:868-879.
56. Mekle R, Mlynarik V, Gambarota G, et al. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 2009; 61:1279-1285.
57. Deelchand DK, Van de Moortele PF, Adriany G, et al. In vivo 1H NMR spectroscopy of the human brain at 9.4 T: initial results. J Magn Reson 2010; 206:74-80.
58. Stephenson MC, Gunner F, Napolitano A, et al. Applications of multinuclear magnetic resonance spectroscopy at 7T. World J Radiol 2011; 3:105-113.
59. Nelson SJ, Xu D, Hammond KE, et al. 3-D MRSI of patients with gliomas using a 7T whole body MR scanner. In: Proceedings of the 15th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 2007; Berlin, Germany. p. 1241.
60. de Graaf RA, Brown PB, McIntyre S, et al. High magnetic field water and metabolite proton T1 and T2 relaxation in rat brain in vivo. Magn Reson Med 2006; 56:386-394. (Pubitemid 44162787)
61. Li Y, Xu D, Chen AP, et al. Proton spectroscopy of human brain at 3T and 7T: signal-to-noise ratio, spectral linewidth and relaxation times. In: Proceedings of the 16th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 2008; Toronto, Ontario, Canada. p. 1592.
62. Tkac I, Andersen P, Adriany G, et al. In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn Reson Med 2001; 46:451-456. (Pubitemid 32831318)
63. Henning A, Fuchs A, Murdoch JB, et al. Slice-selective FID acquisition, localized by outer volume suppression (FIDLOVS) for (1)H-MRSI of the human brain at 7 T with minimal signal loss. NMR Biomed 2009; 22:683-696.
64. Li Y, Chen AP, Larson P, et al. Short-echo spin-echo localization MRSI in gliomas at 7 Tesla. In: Proceedings of the 19th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 2011; Montreal, Quebec, Canada. p. 1423.
65. Terpstra M, Ugurbil K, Tkac I. Noninvasive quantification of human brain ascorbate concentration using 1H NMR spectroscopy at 7 T. NMR Biomed 2009; 23:227-232.
66. Choi C, Ghose S, Uh J, et al. Measurement of N-acetylaspartylglutamate in the human frontal brain by 1H-MRS at 7 T. Magn Reson Med 2010; 64:1247-1251.
67. Choi C, Douglas D, Hawesa H, et al. Measurement of glycine in human prefrontal brain by point-resolved spectroscopy at 7.0 tesla in vivo. Magn Reson Med 2009; 62:1305-1310.
68. Choi C, Dimitrov IE, Douglas D, et al. Improvement of resolution for brain coupled metabolites by optimized (1)H MRS at 7T. NMR Biomed 2010; 23:1044-1052.
69. Choi C, Dimitrov I, Douglas D, et al. In vivo detection of serine in the human brain by proton magnetic resonance spectroscopy (1H-MRS) at 7 Tesla. Magn Reson Med 2009; 62:1042-1046.
70. Srinivasan R, Phillips JJ, Vandenberg SR, et al. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol 2010; 12:1152-1161.
71. Elkhaled A, Jalbert L, Yoshihara H, et al. Metabolic characterization of recurrent grade 2 glioma using proton HR-MAS spectroscopy. In: Proceedings of the 19th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 2011; Montreal, Quebec, Canada. p. 182.
72. Jalbert L, Elkhaled A, Srinivasan R, et al. Presence of 2-hydroxyglutarate in IDH1 mutated low-grade glioma using ex vivo proton HR-MAS spectroscopy. In: Proceedings of the 19th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 2011; Montreal, Quebec, Canada. p. 183.
73. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
74. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
75. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120:707-718.
76. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75:1560-1566.
77. Qiao H, Zhang X, Zhu XH, et al. In vivo 31P MRS of human brain at high/ultrahigh fields: a quantitative comparison of NMR detection sensitivity and spectral resolution between 4 T and 7 T. Magn Reson Imaging 2006; 24:1281-1286. (Pubitemid 44827580)
78. Atkinson IC, Sonstegaard R, Pliskin NH, et al. Vital signs and cognitive function are not affected by 23-sodium and 17-oxygen magnetic resonance imaging of the human brain at 9.4 T. J Magn Reson Imaging 2010; 32:82-87.
79. Atkinson IC, Thulborn KR. Feasibility of mapping the tissue mass corrected bioscale of cerebral metabolic rate of oxygen consumption using 17-oxygen and 23-sodium MR imaging in a human brain at 9.4 T. Neuroimage 2010; 51:723-733.
80. Fleysher L, Oesingmann N, Stoeckel B, et al. Sodium long-component T2 mapping in human brain at 7 Tesla. Magn Reson Med 2009; 62:1338-1341.
81. Thulborn KR, Lu A, Atkinson IC, et al. Quantitative sodium MR imaging and sodium bioscales for the management of brain tumors. Neuroimaging Clin N Am 2009; 19:615-624.